Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.


Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
01 04 2022
Historique:
pubmed: 16 10 2021
medline: 5 4 2022
entrez: 15 10 2021
Statut: ppublish

Résumé

Diagnostic classification of diffuse gliomas now requires an assessment of molecular features, often including IDH-mutation and 1p19q-codeletion status. Because genetic testing requires an invasive process, an alternative noninvasive approach is attractive, particularly if resection is not recommended. The goal of this study was to evaluate the effects of training strategy and incorporation of biologically relevant images on predicting genetic subtypes with deep learning. Our dataset consisted of 384 patients with newly diagnosed gliomas who underwent preoperative MRI with standard anatomical and diffusion-weighted imaging, and 147 patients from an external cohort with anatomical imaging. Using tissue samples acquired during surgery, each glioma was classified into IDH-wildtype (IDHwt), IDH-mutant/1p19q-noncodeleted (IDHmut-intact), and IDH-mutant/1p19q-codeleted (IDHmut-codel) subgroups. After optimizing training parameters, top performing convolutional neural network (CNN) classifiers were trained, validated, and tested using combinations of anatomical and diffusion MRI with either a 3-class or tiered structure. Generalization to an external cohort was assessed using anatomical imaging models. The best model used a 3-class CNN containing diffusion-weighted imaging as an input, achieving 85.7% (95% CI: [77.1, 100]) overall test accuracy and correctly classifying 95.2%, 88.9%, 60.0% of the IDHwt, IDHmut-intact, and IDHmut-codel tumors. In general, 3-class models outperformed tiered approaches by 13.5%-17.5%, and models that included diffusion-weighted imaging were 5%-8.8% more accurate than those that used only anatomical imaging. Training a classifier to predict both IDH-mutation and 1p19q-codeletion status outperformed a tiered structure that first predicted IDH-mutation, then 1p19q-codeletion. Including apparent diffusion coefficient (ADC), a surrogate marker of cellularity, more accurately captured differences between subgroups.

Sections du résumé

BACKGROUND
Diagnostic classification of diffuse gliomas now requires an assessment of molecular features, often including IDH-mutation and 1p19q-codeletion status. Because genetic testing requires an invasive process, an alternative noninvasive approach is attractive, particularly if resection is not recommended. The goal of this study was to evaluate the effects of training strategy and incorporation of biologically relevant images on predicting genetic subtypes with deep learning.
METHODS
Our dataset consisted of 384 patients with newly diagnosed gliomas who underwent preoperative MRI with standard anatomical and diffusion-weighted imaging, and 147 patients from an external cohort with anatomical imaging. Using tissue samples acquired during surgery, each glioma was classified into IDH-wildtype (IDHwt), IDH-mutant/1p19q-noncodeleted (IDHmut-intact), and IDH-mutant/1p19q-codeleted (IDHmut-codel) subgroups. After optimizing training parameters, top performing convolutional neural network (CNN) classifiers were trained, validated, and tested using combinations of anatomical and diffusion MRI with either a 3-class or tiered structure. Generalization to an external cohort was assessed using anatomical imaging models.
RESULTS
The best model used a 3-class CNN containing diffusion-weighted imaging as an input, achieving 85.7% (95% CI: [77.1, 100]) overall test accuracy and correctly classifying 95.2%, 88.9%, 60.0% of the IDHwt, IDHmut-intact, and IDHmut-codel tumors. In general, 3-class models outperformed tiered approaches by 13.5%-17.5%, and models that included diffusion-weighted imaging were 5%-8.8% more accurate than those that used only anatomical imaging.
CONCLUSION
Training a classifier to predict both IDH-mutation and 1p19q-codeletion status outperformed a tiered structure that first predicted IDH-mutation, then 1p19q-codeletion. Including apparent diffusion coefficient (ADC), a surrogate marker of cellularity, more accurately captured differences between subgroups.

Identifiants

pubmed: 34653254
pii: 6398212
doi: 10.1093/neuonc/noab238
pmc: PMC8972294
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

639-652

Subventions

Organisme : NCI NIH HHS
ID : P01 CA118816
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097257
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007175
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Sci Rep. 2017 Oct 17;7(1):13396
pubmed: 29042619
Clin Cancer Res. 2017 Oct 15;23(20):6078-6085
pubmed: 28751449
Neurooncol Adv. 2020 Jul 17;2(1):vdaa066
pubmed: 32705083
J Neurooncol. 2014 Sep;119(2):377-85
pubmed: 24874469
Sci Rep. 2017 Jul 14;7(1):5467
pubmed: 28710497
Neuroimage. 2017 Dec;163:115-124
pubmed: 28765056
Sci Data. 2017 Sep 05;4:170117
pubmed: 28872634
Clin Cancer Res. 2009 Oct 1;15(19):6002-7
pubmed: 19755387
AJNR Am J Neuroradiol. 2018 Jan;39(1):37-42
pubmed: 29122763
Clin Cancer Res. 2018 Sep 15;24(18):4429-4436
pubmed: 29789422
PLoS Med. 2018 Nov 27;15(11):e1002699
pubmed: 30481176
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Oncol Lett. 2014 Jun;7(6):1895-1902
pubmed: 24932255
Neuro Oncol. 2020 Mar 5;22(3):402-411
pubmed: 31637430
Neuro Oncol. 2020 Jul 7;22(7):936-943
pubmed: 32064507
Neuro Oncol. 2014 Nov;16(11):1478-83
pubmed: 24860178
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Brain Pathol. 2020 Jul;30(4):844-856
pubmed: 32307792
J Neuropathol Exp Neurol. 2019 Apr 1;78(4):294-296
pubmed: 30830209
Neuroradiology. 2021 Mar;63(3):353-362
pubmed: 32840682
AJNR Am J Neuroradiol. 2018 Jul;39(7):1201-1207
pubmed: 29748206
IEEE Trans Med Imaging. 2015 Oct;34(10):1993-2024
pubmed: 25494501
Neuro Oncol. 2018 Sep 3;20(10):1393-1399
pubmed: 29590424
Neuroimage. 2002 Oct;17(2):825-41
pubmed: 12377157
Clin Cancer Res. 2019 Dec 15;25(24):7455-7462
pubmed: 31548344
Science. 2011 Jul 22;333(6041):425
pubmed: 21719641
Neuro Oncol. 2021 Feb 25;23(2):304-313
pubmed: 32706862
Front Neurosci. 2013 Apr 04;7:41
pubmed: 23596381
J Med Syst. 2019 Jul 11;43(8):279
pubmed: 31297614
AJR Am J Roentgenol. 2018 Mar;210(3):621-628
pubmed: 29261348
Clin Cancer Res. 2018 Mar 1;24(5):1073-1081
pubmed: 29167275
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Lancet Oncol. 2014 Aug;15(9):e395-403
pubmed: 25079102
Eur Radiol. 2020 Feb;30(2):844-854
pubmed: 31446467
Brain Pathol. 2019 Jul;29(4):469-472
pubmed: 31038238
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
Neuro Oncol. 2017 Jan;19(1):109-117
pubmed: 27353503

Auteurs

Julia Cluceru (J)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Yannet Interian (Y)

MS in Analytics Program, University of San Francisco, San Francisco, California, USA.

Joanna J Phillips (JJ)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Department of Pathology, University of California, San Francisco, San Francisco, California, USA.

Annette M Molinaro (AM)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Tracy L Luks (TL)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Paula Alcaide-Leon (P)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.
Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.

Marram P Olson (MP)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Devika Nair (D)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Marisa LaFontaine (M)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Anny Shai (A)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Pranathi Chunduru (P)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Valentina Pedoia (V)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Javier E Villanueva-Meyer (JE)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Susan M Chang (SM)

Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.

Janine M Lupo (JM)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH